These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21869689)

  • 1. Comparing the influence of dopamine D₂ polymorphisms and plasma drug concentrations on the clinical response to risperidone.
    Yasui-Furukori N; Tsuchimine S; Saito M; Nakagami T; Sugawara N; Fujii A; Kaneko S
    J Clin Psychopharmacol; 2011 Oct; 31(5):633-7. PubMed ID: 21869689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients.
    Yasui-Furukori N; Saito M; Nakagami T; Furukori H; Suzuki A; Kondo T; Kaneko S
    J Psychopharmacol; 2010 Jul; 24(7):987-94. PubMed ID: 19477882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
    Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
    Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients.
    Yasui-Furukori N; Saito M; Tsuchimine S; Nakagami T; Sato Y; Sugawara N; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1491-5. PubMed ID: 18579277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia.
    Sakumoto N; Kondo T; Mihara K; Suzuki A; Yasui-Furukori N
    Psychiatry Clin Neurosci; 2007 Apr; 61(2):174-80. PubMed ID: 17362435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients.
    Wu S; Xing Q; Gao R; Li X; Gu N; Feng G; He L
    Neurosci Lett; 2005 Mar; 376(1):1-4. PubMed ID: 15694263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.
    Wang L; Yu L; Zhang AP; Fang C; Du J; Gu NF; Qin SY; Feng GY; Li XW; Xing QH; He L
    J Psychopharmacol; 2007 Nov; 21(8):837-42. PubMed ID: 17715206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy.
    Klampfl K; Taurines R; Preuss A; Burger R; Rothenhöfer S; Wewetzer Ch; Pfuhlmann B; Fegert J; Gerlach M; Mehler-Wex C
    Pharmacopsychiatry; 2010 Mar; 43(2):58-65. PubMed ID: 20336598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDR1 gene polymorphisms and response to acute risperidone treatment.
    Kastelic M; Koprivsek J; Plesnicar BK; Serretti A; Mandelli L; Locatelli I; Grabnar I; Dolzan V
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):387-92. PubMed ID: 20060871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.
    Yoshimura R; Shinkai K; Ueda N; Nakamura J
    Pharmacopsychiatry; 2007 Jan; 40(1):9-13. PubMed ID: 17327954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone.
    Yamanouchi Y; Iwata N; Suzuki T; Kitajima T; Ikeda M; Ozaki N
    Pharmacogenomics J; 2003; 3(6):356-61. PubMed ID: 14610521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of DRD2 polymorphisms on the clinical outcomes of patients with schizophrenia.
    Zahari Z; Teh LK; Ismail R; Razali SM
    Psychiatr Genet; 2011 Aug; 21(4):183-9. PubMed ID: 21206399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
    Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
    J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence on the schizophrenic symptoms by the DRD2Ser/Cys311 and -141C Ins/Del polymorphisms.
    Himei A; Koh J; Sakai J; Inada Y; Akabame K; Yoneda H
    Psychiatry Clin Neurosci; 2002 Feb; 56(1):97-102. PubMed ID: 11929577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients.
    Xing Q; Gao R; Li H; Feng G; Xu M; Duan S; Meng J; Zhang A; Qin S; He L
    Pharmacogenomics; 2006 Oct; 7(7):987-93. PubMed ID: 17054409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association study between antipsychotics- induced restless legs syndrome and polymorphisms of dopamine D1, D2, D3, and D4 receptor genes in schizophrenia.
    Kang SG; Lee HJ; Choi JE; Park YM; Park JH; Han C; Kim YK; Kim SH; Lee MS; Joe SH; Jung IK; Kim L
    Neuropsychobiology; 2008; 57(1-2):49-54. PubMed ID: 18451638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients.
    Yoshimura R; Hori H; Sugita A; Ueda N; Kakihara S; Umene W; Nakano Y; Shinkai K; Mitoma M; Ohta M; Shinkai T; Nakamura J
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1072-7. PubMed ID: 17459549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.
    Spina E; Avenoso A; Facciolà G; Salemi M; Scordo MG; Ancione M; Madia AG; Perucca E
    Psychopharmacology (Berl); 2001 Jan; 153(2):238-43. PubMed ID: 11205425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risperidone plasma levels, clinical response and side-effects.
    Riedel M; Schwarz MJ; Strassnig M; Spellmann I; Müller-Arends A; Weber K; Zach J; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2005 Aug; 255(4):261-8. PubMed ID: 15565299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.